ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013Guideline
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Archives of pathology & laboratory medicine · 2013Guideline
- Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.Clinical lung cancer · 2026Article
- Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.NPJ precision oncology · 2026Article
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nature reviews. Clinical oncology · 2025Review
- Trends and regional variations in chronic ischemic heart disease and lung cancer-related mortality among American adults: Insights from retrospective CDC wonder analysis.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Article
- [Research Progress of Treatment for NSCLC in Young Patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Racial disparities in the genetic landscape of lung cancer.Cancer health disparities · 2022Article
- Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model.EBioMedicine · 2021Article
- Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.Clinical lung cancer · 2020Article
- Cancer in Africa: Is It a Genetic or Environmental Health Problem?Frontiers in oncology · 2020Review
- Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center.Oncotarget · 2019Article
- Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil.Journal of neuropathology and experimental neurology · 2019Article
- Identification of key pathways and genes in lung carcinogenesis.Oncology letters · 2018Article
- Lung cancer health disparities.Carcinogenesis · 2018Review
- Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Therapeutic advances in drug safety · 2018Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies in non-small-cell lung cancer (NSCLC) have demonstrated a wide variation in responsiveness to epidermal growth factor receptor (EGFR) -targeting agents and in genetic aberrancies of the EGFR pathway according to ethnic background, most notably a higher frequency of activating EGFR mutations among East-Asian patients. We investigated the frequency of EGFR pathway aberrancies among African American patients with NSCLC, for whom limited information presently exists. PATIENTS AND
methodsEGFR fluorescent in situ hybridization (FISH) was performed on archived tissues from 53 African American patients. Extracted DNA was sequenced for mutational analysis of EGFR exons 18 to 21 and KRAS exon 2. Results were compared by multivariate analysis to an historical control cohort of 102 white patients with NSCLC.
resultsAfrican Americans were significantly less likely to harbor activating mutations of EGFR than white patients (2% v 17%; P = .022). Only one EGFR mutation was identified, a novel S768N substitution. EGFR FISH assay was more frequently positive for African Americans than for white patients (51% v 32%; P = .018). KRAS mutational frequency did not differ between the groups (23% v 21%; P = .409).
conclusionAfrican American patients with NSCLC are significantly less likely than white counterparts to harbor activating mutations of EGFR, which suggests that EGFR tyrosine kinase inhibitors (TKIs) are unlikely to yield major remissions in this population. Our findings add to a growing body of evidence that points to genetic heterogeneity of the EGFR pathway in NSCLC among different ethnic groups and that underscores the need for consideration of these differences in the design of future trials of agents that target the EGFR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.